Given the dysfunction in the American medical system in the response to Acute COVID, it is not surprising that this dysfunction extends to the treatment of Post-Acute Sequela of COVID-19 (PASC) or Long COVID. The problem with the system’s response to the long-term manifestations of the acute disease is the average medical provider in the…
Science, and specifically the practice of medicine, requires discourse. Discourse includes many forms, from lively debates on opposing hypotheses to collaboration and sharing of ideas. This past weekend at the FLCCC Inaugural Educational Conference of Spike Induced Diseases (https://covid19criticalcare.com/flccc-educational-conference-october-15-2022/), collaboration, mutual respect, and knowledge sharing were the foundation of the event.
The writing is on the wall, even at Fox News. The obvious collusion between big Pharma and the American government is completely out of control. We have been waiting for a Rosa Parks moment, this might be it.
The SARS-CoV-2 Omicron BA.2.75 variant emerged in May 2022. BA.2.75 is a BA.2 descendant but is phylogenetically distinct from BA.5, the currently predominant BA.2 descendant. Here, we show that BA.2.75 has a greater effective reproduction number and different immunogenicity profile than BA.5. We determined the sensitivity of BA.2.75 to vaccinee and convalescent sera as well as a panel of clinically available antiviral drugs and antibodies. Antiviral drugs largely retained potency, but antibody sensitivity varied depending on several key BA.2.75-specific substitutions. The BA.2.75 spike exhibited a profoundly higher affinity for its human receptor, ACE2. Additionally, the fusogenicity, growth efficiency in human alveolar epithelial cells, and intrinsic pathogenicity in hamsters of BA.2.75 were greater than those of BA.2. Our multilevel investigations suggest that BA.2.75 acquired virological properties independent of BA.5, and the potential risk of BA.2.75 to global health is greater than that of BA.5.
To construct synthetic variants of natural coronaviruses in the lab, researchers often use a method called in vitro genome assembly. This method utilizes special enzymes called restriction enzymes to generate DNA building blocks that then can be “stitched” together in the correct order of the viral genome. To make a virus in the lab, researchers usually engineer the viral genome to add and remove stitching sites, called restriction sites. The ways researchers modify these sites can serve as fingerprints of in vitro genome assembly.
A new study on Covid-19’s infection fatality rate (IFR) by age from a team led by Dr. John Ioannidis, the world’s most-cited physician, estimates that Covid’s IFR in the pre-vaccine era was under 0.1% for those under 70—even lower than previously believed.
Dr. Jessica Rose, PhD, talks data about the alarming dangers of COVID-19 vaccines and the tribulations of speaking out on behalf of humanity, at the peril of reputation, career, family and friends.
SW proposed to conduct the study, RH and SW designed the study. Both authors independently converted the pdf data disclosed by the Japanese government into excel files and confirmed data matched. Then data collection, classification, and analyses were done first by the SW and later confirmed by RH, with any discrepancies being discussed and decided…
Dr. Cole is a board-certified dermatopathologist (AP & CP) and the CEO/Medical Director of Cole Diagnostics. He has worked as an independent pathologist since 2004. Some highlights from his CV: Ackerman Academy of Dermatopathology (July 2002-June 2003): Dermatopathology Fellowship (Chief Fellow). Mayo Clinic (July 1997-June 2002): Resident in Anatomic and Clinical Pathology. Chief Fellow, Surgical…
